Jared Kaltwasser

A consensus definition of high genomic complexity in chronic lymphocytic leukemia may be less important than analyzing the contributions of individual biomarkers.

Many MASH cirrhosis trials use histologic endpoints, but a new review finds limited standardization of these outcomes across studies.

Chimeric antigen receptor-based immunotherapies show promise when directed at viral targets, but data are limited.

The benefits of exercise are particularly notable for patients who are dependent upon dialysis, a new review suggests.

Delgocitinib led to notable improvement by week 4, which may have helped improve longer-term treatment adherence.

A new review explains how new therapies and technologies are guiding the treatment of acute myeloid leukemia (AML).

Previous inquiries into the associations between sleep disorders were limited by small sample sizes, according to researchers.

At 24 months, patients receiving iptacopan had approximately half the decline in estimated glomerular filtration rate slope compared to those receiving placebo.

Patients who saw hair specialist dermatologists tended to be prescribed more therapies for their scarring alopecia.

Evidence suggests new therapies like GLP-1 receptor agonists, initially approved to treat obesity and diabetes, can also benefit patients with liver disease.

New strategies and therapies are being developed to try and decrease the risk of bone disease and cardiovascular complications among people with severe kidney disease.

At-home phototherapy is more convenient than in-office care, and investigators found its one-time costs are also far less than the cost of care in a clinic.

Ultrasound AI models use radiomics and deep learning to predict DLBCL survival, enabling low-cost, noninvasive risk stratification.

MASH can have a significant impact on patients’ quality of life, particularly if they have comorbidities or advanced fibrosis.

A new study suggests that incorporating proteomic data can help refine risk stratification in mantle cell lymphoma (MCL).

Attempts to refine non–small cell lung cancer treatment selection have been limited by a lack of biomarkers, but recent research is expanding the potential landscape.

Topical immunotherapy remains an effective, affordable option for alopecia areata, with long-term control seen in multimodal treatment approaches.

It may be possible to detect Richter transformation (RT) years before it actually occurs in patients with chronic or small lymphocytic leukemia, research indicates.

Racial and ethnic disparities in outcomes persist in acute myeloid leukemia, but such disparities may not be tied to the use of tyrosine kinase inhibitors, according to a new report.

Patients with CSU with isolated angioedema tended to have more severe attacks and an inferior response to high-dose antihistamines.

A program in Detroit identified hundreds of patients with chronic kidney disease.

Scalp tape strip samples had high concordance with lesion biopsies in patients with alopecia areata.

Patients with chronic or small lymphocytic leukemia now have a variety of treatment options, although a new report found not every patient was presented with multiple options.

The findings bolster the case for using Bruton tyrosine kinase inhibitors in the treatment of Richter syndrome.

Patients identified as having a Janus kinase inhibitor responder profile were much more likely to respond positively to the class of atopic dermatitis therapies.

A new nasal spray for patients with chronic spontaneous urticaria could eliminate the need for injectable epinephrine.

The tools are particularly helpful for pediatric patients, who often experience psychosocial impacts from the disease.

Environmental factors were a barrier to participation in community activities among people with multiple sclerosis, even after adjusting for personal factors like disease severity.

A new review highlights the potential to develop ways to better anticipate and treat Richter transformation in patients with chronic lymphocytic leukemia.

In a cohort of veterans with steatotic liver disease, patients with metabolic- and alcohol-associated liver disease had the lowest incidence of cirrhosis.